(600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600513 · · 11 pages · Chinese
Summary by 6ix AI
The report indicates a decrease in revenue compared to the same period last year, alongside a notable decline in net profit attributable to shareholders. The company assures that the report's content is accurate and complete, with no false statements or omissions. The financial statements included in the report have not been audited.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Lianhuan Pharmaceutical Co., Ltd. on 6ix
Earlier from Jiangsu Lianhuan Pharmaceutical
- (600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization
- (600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Receipt of Approval Notice for Drug Supplementary Application
- Announcement on Outline of the 2026 Semi-annual Performance Briefing
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
Follow Jiangsu Lianhuan Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Lianhuan Pharmaceutical